A pan-cancer blueprint of genomics alterations and transcriptional regulation of Siglecs, and implications in prognosis and immunotherapy responsiveness
机构:[1]Beijing Key Laboratory for Genetics of Birth Defects, Beijing Pediatric Research Institute, MOE Key Laboratory of Major Diseases in Children, Rare Disease Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China首都医科大学附属北京儿童医院[2]Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China[3]Beijing ClouDNA Technology Co., Ltd., Beijing, China[4]Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China首都医科大学附属北京同仁医院临床科室耳鼻咽喉-头颈外科[5]Division of Immunotherapy, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA
第一作者机构:[1]Beijing Key Laboratory for Genetics of Birth Defects, Beijing Pediatric Research Institute, MOE Key Laboratory of Major Diseases in Children, Rare Disease Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China[2]Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China
共同第一作者:
通讯作者:
通讯机构:[1]Beijing Key Laboratory for Genetics of Birth Defects, Beijing Pediatric Research Institute, MOE Key Laboratory of Major Diseases in Children, Rare Disease Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China[5]Division of Immunotherapy, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA[*1]Beijing Key Laboratory for Genetics of Birth Defects, Beijing Pediatric Research Institute, MOE Key Laboratory of Major Diseases in Children, Rare Disease Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China.
推荐引用方式(GB/T 7714):
Mei Song,Huang Yixuan,Zhao Yan,et al.A pan-cancer blueprint of genomics alterations and transcriptional regulation of Siglecs, and implications in prognosis and immunotherapy responsiveness[J].CLINICAL AND TRANSLATIONAL MEDICINE.2023,13(5):e1262.doi:10.1002/ctm2.1262.
APA:
Mei Song,Huang Yixuan,Zhao Yan,Zhang Xinlei&Zhang Peng.(2023).A pan-cancer blueprint of genomics alterations and transcriptional regulation of Siglecs, and implications in prognosis and immunotherapy responsiveness.CLINICAL AND TRANSLATIONAL MEDICINE,13,(5)
MLA:
Mei Song,et al."A pan-cancer blueprint of genomics alterations and transcriptional regulation of Siglecs, and implications in prognosis and immunotherapy responsiveness".CLINICAL AND TRANSLATIONAL MEDICINE 13..5(2023):e1262